Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2020, with a specific reporting date of February 21, 2020. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a regulatory disclosure of share transactions.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details three specific share transactions executed on February 20, 2020:
- Ms. V. Whyte (Company Secretary): Transferred 10,720 Ordinary Shares between accounts for nil consideration.
- Ms. V. Whyte (Company Secretary): Transferred 10,838 Ordinary Shares to her spouse for nil consideration.
- Mr. I. Whyte (PCA of Ms. V. Whyte): Received 10,838 Ordinary Shares from his spouse for nil consideration.
All transactions involved Ordinary Shares of 25 pence each (ISIN: GB0009252882) and were conducted at a price of £0.00.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the share transfers described above.
Investor Verification Checklist
- Verify the total number of shares transferred between Ms. V. Whyte and Mr. I. Whyte (10,838 shares).
- Confirm that the transactions were executed for nil consideration, indicating no change in beneficial ownership value.
- Note that the filing date (February 21, 2020) follows the transaction date (February 20, 2020) by one day.
- Recognize that this filing contains no financial performance data for the period.